Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Operations: 2009-2024

Historic Cash from Operations for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to -$80.2 million.

  • Fortress Biotech's Cash from Operations rose 69.54% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.1 million, marking a year-over-year increase of 35.30%. This contributed to the annual value of -$80.2 million for FY2024, which is 37.46% up from last year.
  • Latest data reveals that Fortress Biotech reported Cash from Operations of -$80.2 million as of FY2024, which was up 37.46% from -$128.2 million recorded in FY2023.
  • Fortress Biotech's Cash from Operations' 5-year high stood at -$80.2 million during FY2024, with a 5-year trough of -$179.4 million in FY2022.
  • Moreover, its 3-year median value for Cash from Operations was -$128.2 million (2023), whereas its average is -$129.3 million.
  • Per our database at Business Quant, Fortress Biotech's Cash from Operations plummeted by 53.94% in 2022 and then soared by 37.46% in 2024.
  • Yearly analysis of 5 years shows Fortress Biotech's Cash from Operations stood at -$83.7 million in 2020, then slumped by 39.27% to -$116.5 million in 2021, then plummeted by 53.94% to -$179.4 million in 2022, then climbed by 28.53% to -$128.2 million in 2023, then spiked by 37.46% to -$80.2 million in 2024.